AAPL337.39-7.24 (-2.10%) ▼|ABBV288.90-5.99 (-2.03%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|AAPL337.39-7.24 (-2.10%) ▼|ABBV288.90-5.99 (-2.03%) ▼|ABT109.90+3.70 (+3.48%) ▲|ACN262.81+4.57 (+1.77%) ▲|ADBE255.00+4.77 (+1.91%) ▲|AMAT387.78-2.31 (-0.59%) ▼|AMD483.88-20.93 (-4.15%) ▼|AMGN466.59+0.58 (+0.12%) ▲|AMT188.18+0.40 (+0.21%) ▲|AMZN250.14+9.79 (+4.07%) ▲|AVGO329.94+3.86 (+1.18%) ▲|AXP328.87+9.76 (+3.06%) ▲|BA175.65+4.10 (+2.39%) ▲|BAC50.24+0.23 (+0.46%) ▲|BKNG155.04+6.91 (+4.66%) ▲|BLK1,174.62+27.08 (+2.36%) ▲|BMY62.46-0.02 (-0.03%) ▼|BNY148.30+1.19 (+0.81%) ▲|BRK-B554.76+12.27 (+2.26%) ▲|C123.82+1.85 (+1.52%) ▲|CAT623.25+0.50 (+0.08%) ▲|CL96.99+1.70 (+1.78%) ▲|CMCSA23.75+0.53 (+2.28%) ▲|COF212.07+7.22 (+3.52%) ▲|COP147.31-6.72 (-4.36%) ▼|COST1,039.22+26.94 (+2.66%) ▲|CRM232.27+3.10 (+1.35%) ▲|CSCO103.19-1.32 (-1.26%) ▼|CVS88.53-1.73 (-1.91%) ▼|CVX228.15-7.37 (-3.13%) ▼|DE664.40-11.08 (-1.64%) ▼|DHR229.50-2.73 (-1.18%) ▼|DIS113.60+2.66 (+2.40%) ▲|DUK127.93+0.54 (+0.42%) ▲|EMR168.41+3.47 (+2.10%) ▲|FDX319.72+6.44 (+2.06%) ▲|GD369.31-3.29 (-0.88%) ▼|GE315.95+14.15 (+4.69%) ▲|GEV877.20+19.33 (+2.25%) ▲|GILD170.19-0.49 (-0.29%) ▼|GM89.40+2.00 (+2.28%) ▲|GOOG281.97+3.75 (+1.35%) ▲|GOOGL283.48+3.64 (+1.30%) ▲|GS909.74+15.19 (+1.70%) ▲|HD339.46+10.26 (+3.12%) ▲|HON225.16+6.83 (+3.13%) ▲|IBM258.34+0.53 (+0.21%) ▲|INTC61.96-3.81 (-5.79%) ▼|INTU355.56+14.47 (+4.24%) ▲|ISRG444.94+12.93 (+2.99%) ▲|JNJ269.26-3.94 (-1.44%) ▼|JPM341.71+4.67 (+1.38%) ▲|KO95.69+1.61 (+1.71%) ▲|LIN521.96+7.72 (+1.50%) ▲|LLY1,412.61-4.93 (-0.35%) ▼|LMT641.11+4.16 (+0.65%) ▲|LOW216.26+7.19 (+3.44%) ▲|LRCX232.86-6.25 (-2.61%) ▼|MA659.63+21.62 (+3.39%) ▲|MCD263.87+5.75 (+2.23%) ▲|MDLZ66.05+1.11 (+1.70%) ▲|MDT98.69+2.15 (+2.23%) ▲|META612.09-2.90 (-0.47%) ▼|MMM179.35+5.01 (+2.87%) ▲|MO77.51-0.52 (-0.67%) ▼|MRK148.53-0.99 (-0.66%) ▼|MS186.52+2.22 (+1.20%) ▲|MSFT520.02-1.90 (-0.36%) ▼|MU852.74-32.00 (-3.62%) ▼|NEE84.99+1.28 (+1.52%) ▲|NFLX62.60+0.52 (+0.84%) ▲|NKE39.53+0.86 (+2.22%) ▲|NOW108.78+3.66 (+3.48%) ▲|NVDA206.58+1.94 (+0.95%) ▲|ORCL122.29-8.38 (-6.41%) ▼|PEP140.01+2.67 (+1.94%) ▲|PFE30.71+0.19 (+0.61%) ▲|PG163.79+2.22 (+1.37%) ▲|PLTR184.31+0.20 (+0.11%) ▲|PM208.04-0.75 (-0.36%) ▼|QCOM166.20+1.41 (+0.86%) ▲|RTX201.84+2.04 (+1.02%) ▲|SBUX103.86+0.21 (+0.20%) ▲|SCHW89.25+1.20 (+1.36%) ▲|SO94.31+0.60 (+0.64%) ▲|SPG222.83+5.08 (+2.33%) ▲|T21.44+0.03 (+0.14%) ▲|TMO685.44-11.56 (-1.66%) ▼|TMUS158.56+2.12 (+1.36%) ▲|TSLA408.55+8.74 (+2.18%) ▲|TXN308.30+7.46 (+2.48%) ▲|UBER67.19+1.94 (+2.97%) ▲|UNH397.41-9.57 (-2.35%) ▼|UNP307.49+3.49 (+1.15%) ▲|UPS109.57+1.32 (+1.22%) ▲|USB60.52+1.07 (+1.80%) ▲|V426.08+12.49 (+3.02%) ▲|VZ44.94+0.21 (+0.46%) ▲|WFC84.96+1.56 (+1.86%) ▲|WMT126.97+3.46 (+2.80%) ▲|XOM180.46-6.79 (-3.63%) ▼|
19.6 C
New York
Monday, November 2, 2026

Tag: carotid artery

newsFORsourcecompanycontentinformationreleases1market

The changing landscape of neurological conditions across all ages at Zydus Hospital, Vadodara

AHMEDABAD, India, Oct. 23, 2026 /PRNewswire/ -- More than three billion people, over 40 per cent of the world's population, are affected by neurological...

[China’s Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures

SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering...

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Late-Breaking Clinical Trial Results Announced at VIVA 2026

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCarotid artery

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers